TOP TEN perturbations for 39996_at (Homo sapiens)
Organism: Homo sapiens
Gene: 39996_at
Selected probe(set): 206680_at
Platform: Affymetrix Human Genome U133 Plus 2.0 Array
Expression of 39996_at (206680_at) across 6674 perturbations tested by GENEVESTIGATOR:
MALT lymphoma study 1 / normal spleen tissue
Relative Expression (log2-ratio):-6.895544Number of Samples:8 / 6
| Experimental | MALT lymphoma study 1 |
| Human t(11;18)-negative mucosa-associated lymphoid tissue (MALT) lymphoma cells. | |
| Control | normal spleen tissue |
| Normal human spleen tissue sample. |
MALT lymphoma study 2 / normal spleen tissue
Relative Expression (log2-ratio):-6.865176Number of Samples:6 / 6
| Experimental | MALT lymphoma study 2 |
| Human t(11;18)-positive mucosa-associated lymphoid tissue (MALT) lymphoma cells. | |
| Control | normal spleen tissue |
| Normal human spleen tissue sample. |
HCC study 23 (portal vein infiltration) / adjacent liver tissue
Relative Expression (log2-ratio):-3.7776747Number of Samples:3 / 10
| Experimental | HCC study 23 (portal vein infiltration) |
| Tumor liver tissue samples derived from patients with hepatocellular carcinoma (HCC) with portal vein infiltration. Samples were derived by laser capture microdissection (LCM) from patients with HCC from the Chinese National Human Genome Center at Shanghai. | |
| Control | adjacent liver tissue |
| Normal adjacent liver tissue samples derived from patients with hepatocellular carcinoma (HCC). Samples were derived by laser capture microdissection (LCM) from patients with HCC from the Chinese National Human Genome Center at Shanghai. |
HCC study 27 (young; training) / normal liver tissue (young; training)
Relative Expression (log2-ratio):-3.19143Number of Samples:16 / 15
| Experimental | HCC study 27 (young; training) |
| Primary tumor tissue samples obtained from the liver of young patients (≤ 40 years old) with hepatocellular carcinoma assigned to a training cohort. | |
| Control | normal liver tissue (young; training) |
| Normal liver tissue samples obtained from young patients (≤ 40 years old) with hepatocellular carcinoma (HCC) assigned to a training cohort. |
HCV-related HCC study 1 / adjacent HCV-related liver tissue (LC)
Relative Expression (log2-ratio):-2.887598Number of Samples:5 / 4
| Experimental | HCV-related HCC study 1 |
| Hepatitis C infection related human hepatocellular carcinoma sample. | |
| Control | adjacent HCV-related liver tissue (LC) |
| Histologically normal adjacent liver tissue of a patient with Hepatitis C infection related hepatocellular carcinoma. Patient with liver cirrhosis. |
HCC study 27 (elder; training) / normal liver tissue (elder; training)
Relative Expression (log2-ratio):-2.8035202Number of Samples:32 / 24
| Experimental | HCC study 27 (elder; training) |
| Primary tumor tissue samples obtained from the liver of elder patients (> 40 years old) with hepatocellular carcinoma assigned to a training cohort. | |
| Control | normal liver tissue (elder; training) |
| Normal liver tissue samples obtained from elder patients (> 40 years old) with hepatocellular carcinoma (HCC) assigned to a training cohort. |
HCC study 3 (area B) / HCC study 3 (area D)
Relative Expression (log2-ratio):-2.718503Number of Samples:26 / 19
| Experimental | HCC study 3 (area B) |
| Liver tissue biopsy sample from patients with HBV-associated HCC (hepatocellular carcinoma) after orthotopic liver transplantation (OLT) or partial hepatectomy. Tumorous sample was taken from the periphery of the tumor (area B). Patients were positive for hepatitis B surface antigen, antibody to hepatitis B core antigen and antibody to hepatitis B antigen and received antiviral treatment with nucleos(t)ide analogues prior to surgery. | |
| Control | HCC study 3 (area D) |
| Liver tissue biopsy sample from patients with HBV-associated HCC (hepatocellular carcinoma) after orthotopic liver transplantation (OLT) or partial hepatectomy. Non-tumorous sample was taken in an area 2-3 cm away from the tumor (area D). Patients were positive for hepatitis B surface antigen, antibody to hepatitis B core antigen and antibody to hepatitis B antigen and received antiviral treatment with nucleos(t)ide analogues prior to surgery. |
HCC study 3 (area A) / HCC study 3 (area D)
Relative Expression (log2-ratio):-2.7070599Number of Samples:13 / 19
| Experimental | HCC study 3 (area A) |
| Liver tissue biopsy sample from patients with HBV-associated HCC (hepatocellular carcinoma) after orthotopic liver transplantation (OLT) or partial hepatectomy. Tumorous sample was taken from the center of the tumor (area A). Patients were positive for hepatitis B surface antigen, antibody to hepatitis B core antigen and antibody to hepatitis B antigen and received antiviral treatment with nucleos(t)ide analogues prior to surgery. | |
| Control | HCC study 3 (area D) |
| Liver tissue biopsy sample from patients with HBV-associated HCC (hepatocellular carcinoma) after orthotopic liver transplantation (OLT) or partial hepatectomy. Non-tumorous sample was taken in an area 2-3 cm away from the tumor (area D). Patients were positive for hepatitis B surface antigen, antibody to hepatitis B core antigen and antibody to hepatitis B antigen and received antiviral treatment with nucleos(t)ide analogues prior to surgery. |
HCC study 3 (area B) / HCC study 3 (area C)
Relative Expression (log2-ratio):-2.7063398Number of Samples:26 / 24
| Experimental | HCC study 3 (area B) |
| Liver tissue biopsy sample from patients with HBV-associated HCC (hepatocellular carcinoma) after orthotopic liver transplantation (OLT) or partial hepatectomy. Tumorous sample was taken from the periphery of the tumor (area B). Patients were positive for hepatitis B surface antigen, antibody to hepatitis B core antigen and antibody to hepatitis B antigen and received antiviral treatment with nucleos(t)ide analogues prior to surgery. | |
| Control | HCC study 3 (area C) |
| Liver tissue biopsy sample from patients with HBV-associated HCC (hepatocellular carcinoma) after orthotopic liver transplantation (OLT) or partial hepatectomy. Non-tumorous sample was taken from the perilesional area of the tumor (area C). Patients were positive for hepatitis B surface antigen, antibody to hepatitis B core antigen and antibody to hepatitis B antigen and received antiviral treatment with nucleos(t)ide analogues prior to surgery. |
HCC study 3 (area A) / HCC study 3 (area C)
Relative Expression (log2-ratio):-2.6948967Number of Samples:13 / 24
| Experimental | HCC study 3 (area A) |
| Liver tissue biopsy sample from patients with HBV-associated HCC (hepatocellular carcinoma) after orthotopic liver transplantation (OLT) or partial hepatectomy. Tumorous sample was taken from the center of the tumor (area A). Patients were positive for hepatitis B surface antigen, antibody to hepatitis B core antigen and antibody to hepatitis B antigen and received antiviral treatment with nucleos(t)ide analogues prior to surgery. | |
| Control | HCC study 3 (area C) |
| Liver tissue biopsy sample from patients with HBV-associated HCC (hepatocellular carcinoma) after orthotopic liver transplantation (OLT) or partial hepatectomy. Non-tumorous sample was taken from the perilesional area of the tumor (area C). Patients were positive for hepatitis B surface antigen, antibody to hepatitis B core antigen and antibody to hepatitis B antigen and received antiviral treatment with nucleos(t)ide analogues prior to surgery. |